Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases

(2015) Rami Klaff et al.   BJU INTERNATIONAL

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

(2015) Gwenaelle Gravis et al.   EUROPEAN UROLOGY

How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review

(2015) Lara Bellardita et al.   EUROPEAN UROLOGY

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

(2015) Nicholas David James et al.   EUROPEAN UROLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

(2013) Gwenaelle Gravis et al.   LANCET ONCOLOGY

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

(2013) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)

(2012) Catherine M. Tangen et al.   JOURNAL OF UROLOGY

Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer

(2011) Vincenzo Pagliarulo et al.   EUROPEAN UROLOGY

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

(2008) Per Olov Hedlund et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY